Argenx, an esteemed biotech company, appears to remain resilient and unfazed despite emerging competition. The company recently showcased its developments at the
Goldman Sachs 45th Annual Global Healthcare Conference.
Argenx has ceased developing
efgartigimod for AAV. However The
Manufacturers Life Insurance Company has purchased additional shares of the firm, thereby inspiring optimism. Argenx, well ahead of its industry peers, is poised for a blockbuster opportunity with its revolutionary auto-immune disease drug.
Biohaven had a disappointing run while
IQVIA built on its strategic collaboration with argenx. Argenx is preparing to launch
Vyvgart. Unfortunately, there were hits and misses in various therapy trials which have affected its stock prices. The
US FDA has accepted argenx's
VYVGART Hytrulo for CIDP review, giving a much-needed boost to their progress. However,
Argenx's Vyvgart Hytrulo experienced a letdown in the rare disease pemphigus as it fell short of placebo results in ITP trial. Despite the failures, the company holds firm with its auto-immune arena innovation.
J&J's new drug may also give competition to argenx. However, the future appears bright for the firm following the approval of their
VYVGART (efgartigimod alfa) in Japan.
argenx News Analytics from Mon, 17 Jul 2023 07:00:00 GMT to Sun, 09 Jun 2024 10:28:09 GMT -
Rating -3
- Innovation 5
- Information 8
- Rumor 2
